CTMX (CytomX Therapeutics) Tariff Resilience Score: 8/10 (As of Jun. 28, 2026)


CTMX CytomX Therapeutics Inc CTMX
36 GF Score
Price $3.38
GF Value $0.28
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is CytomX Therapeutics Tariff Resilience Score?

CytomX Therapeutics CTMX +3.66% 36 Tariff Resilience Score is 8 as of Jun. 28, 2026. GuruFocus rates CTMX with a GF Score™ of 36/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,376 Biotechnology companies, CytomX Therapeutics ranks better than 98.69% on this metric.

CytomX Therapeutics has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

CytomX Therapeutics has CytomX Therapeutics Inc has high resilience to tariffs due to its focus on domestic markets and limited reliance on international supply chains. The company has not been significantly affected by past tariffs and has strong pricing power in its niche market.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes CytomX Therapeutics might have Highly Resilient.

CytomX Therapeutics  (NAS:CTMX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

CytomX Therapeutics Tariff Resilience Score Related Terms

CTMX vs SMNR, AURA, OMER: Tariff Resilience Score Comparison

For the Biotechnology subindustry, CytomX Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytomX Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where CytomX Therapeutics's Tariff Resilience Score falls into.


CTMX
36GF Score
CytomX Therapeutics Inc CTMX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
CytomX Therapeutics (CTMX) has a Tariff Resilience Score of 8 as of Jun. 28, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, CytomX Therapeutics ranks #18 out of 1376 companies in the Biotechnology industry, placing it in the top 1.3%.
Is CytomX Therapeutics' Tariff Resilience Score too high?
CytomX Therapeutics' current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. CytomX Therapeutics' value of 8 is 100% above this industry median. Based on the distribution chart, CytomX Therapeutics ranks #18 out of 1376 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CytomX Therapeutics has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CytomX Therapeutics' Tariff Resilience Score compare to SMNR and AURA?
According to the Biotechnology industry distribution chart, CytomX Therapeutics ranks #18 out of 1376 companies for Tariff Resilience Score. This places CytomX Therapeutics in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. CytomX Therapeutics' value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,376 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CytomX Therapeutics's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CytomX Therapeutics's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytomX Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CytomX Therapeutics (CTMX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $3.38 — trading 1107.1% above its estimated fair value. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. CytomX Therapeutics' overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For CytomX Therapeutics (CTMX), the current Tariff Resilience Score is 8 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CytomX Therapeutics (CTMX) Overvalued in 2026?

Based on GuruFocus' analysis, CytomX Therapeutics stock appears to be overvalued. The current stock price of $3.38 is trading 1107.1% above its estimated GF Value™ of $0.28. GuruFocus considers CytomX Therapeutics to be Significantly Overvalued.

Key valuation signals for CTMX:

  • Tariff Resilience Score: 8
  • GF Value™: $0.28 vs. price of $3.38 (1107.1% above fair value)
  • GF Score™: 36/100 with 4 warning signs
  • Industry Position: 100% above the Biotechnology median (#18 of 1376)

No single metric tells the full story. See the CTMX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CytomX Therapeutics Business Description

Other Exchanges 6C1:Germany
Address 151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
36GF Score

Get the complete analysis for CTMX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.38
Price
$0.28
GF Value